Past Issues – Page 4 – The Cancer Letter Publications

Past issues are only available to subscribers. If you are not a member, click here to join.

Issue 12 - Mar. 22, 2019

TCL45-12 (237 downloads)

Texas cancer researchers vying to renew CPRIT beyond its 2023 sunset date
The institute is spending more than NCI in the state
The Cancer Prevention and Research Institute of Texas—the second largest publicly-funded granting organization for cancer after NIH—may receive $3 billion more to stay open past its current sunset date in 2023.
Conversation with The Cancer Letter
James Willson: CPRIT is money well spent
Advocates of renewing the Cancer Prevention and Research Institute of Texas argue that the agency is a good investment for the state.
In Brief
- Françoise Mornex becomes first female recipient of Heine H. Hansen Award
- Gift to UPMC Children’s Hospital of Pittsburgh establishes treatment suite for rare early childhood cancer
Funding Opportunities
DoD Prostate Cancer Research Program announces funding opportunities
The FY19 Defense Appropriation provides $100 million to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.
Trials & Tribulations
SWOG’s 1501 study takes aim at the silo wall between cardiology and oncology
Many have written and spoken about the goal of eliminating the effect of developing and delivering medical care in “silos.”
Clinical Roundup
- Breast ultrasound and cancer detection rates increased under new laws
- Duke study says genomic testing associated with lower health care costs in high-risk breast cancer patients
- Braftovi with Mektovi + Erbitux or panitumumab recommended in advanced BRAF-mutant colorectal
- Data from GARNET study indicates robust activity of dostarlimab in endometrial cancer
Drugs & Targets
- Tecentriq + chemo gets FDA approval in extensive-stage SCLC
- Strata Oncology launches expanded StrataNGS
- Oncoceutics and NCI collaborate to develop ONC206
- FDA issues warning letters to breast implant manufacturers to deliver on post-approval requirements

Issue 11 - Mar. 15, 2019

TCL45-11 (296 downloads)

News Analysis
The Gottlieb-Sharpless-Lowy rearrangement
No prizes should be handed out to anyone who predicted that:
1. Scott Gottlieb would leave his job as FDA commissioner,
2. Gottlieb would suggest NCI Director Ned Sharpless as his replacement, and
3. NCI Deputy Director Doug Lowy would step in as NCI acting director.
Trump proposal for FY2020 to slash NIH by 12 percent, NCI by 15 percent
President Donald Trump has proposed to cut $4.7 billion from the NIH budget, with almost $900 million coming out of NCI during the fiscal year 2020.
AACR News
DuBois to receive Magaret Foti award; Freireich–Lifetime Achievement award; Hudson and Robison–Team Science award
The American Association for Cancer Researc will honor the following cancer researchers, clinicians, and physician-scientists at the AACR Annual Meeting 2019, to be held March 29-April 3 in Atlanta.
ASCO News
Hortobagyi to deliver Karnofsky lecture; Brugge–Science of Oncology lecture; Wolmark–Gianni Bonadonna lecture
The American Society of Clinical Oncology and ASCO’s Conquer Cancer Foundation announced the winners of Special Awards, the society’s highest honors, and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards.
In Brief
- Fred Hirsch to join Mount Sinai Tisch Cancer Institute
- Reps. Higgins, Guthrie, Matsui and Bilirakis announce the Cancer Drug Parity Act
- Ong named a finalist in the 25th Annual NIHCM Research and Journalism Awards
Conversation with The Cancer Letter
TMIST PI Pisano: “Are we further reducing breast cancer mortality the more intensively we screen?”
The Tomosynthesis Mammographic Imaging Screening Trial, a massive randomized trial of early detection, is asking an important question:
Is digital breast tomosynthesis better than digital mammography in reducing development of advanced breast cancer?
Clinical Roundup
- UAMS study shows potential to alter neck dissection surgery in head and neck cancer
Drugs & Targets
- European Commission approves Keytruda + chemotherapy for NSCLC
- Tecentriq + Abraxane regimen gets accelerated approval for breast cancer
- Trazimera, Herceptin biosimilar, gets FDA approval
- myPath melanoma test receives Medicare coverage

Issue 10 - Mar. 8, 2019

TCL45-10 (401 downloads)

Trump’s proposal for pediatric cancer has NCI envisioning the first data federation of its kind
In anticipation of an infusion of funds from Congress, NCI is developing a blueprint for a comprehensive cancer data federation—starting with pediatric cancer.
Conversation with The Cancer Letter
Sharpless: With $500 million, NCI can create data federation that would change research in childhood cancer
If this effort is highly successful for childhood cancer, then we’ll broaden the efforts to other cancers next. This is an important first step in learning how useful radical data sharing and aggregation can be.
Conversation with The Cancer Letter
CHOP’s Resnick: Big data will transition from research to the standard of care in the clinic
It’s extremely exciting to hear and see both the NCI and the administration and other community partners and patient groups really coming together and reconsidering, ‘What are the unmet needs that can inform in new ways through new approaches of integration?
Conversation with The Cancer Letter
St. Jude’s Roberts: “No single institution can maximize cures and minimize toxicities alone”
Historically, cancer research drug development has largely been focused upon adult cancers with drugs trickling down to pediatric trials over time. But we now know that 55 percent of the driver mutations are unique to childhood cancers. So, relying upon that old model is not going to serve children well.
Guest Editorial
Needed: A fully funded data federation for pediatric cancer with deep genomic sequencing and clinical records
It was a thrilling moment for me when, sitting on my living room couch, listening to the State of the Union address, I heard the president say:
“Many childhood cancers have not seen new therapies in decades. My budget will ask the Congress for $500 million over the next 10 years to fund this critical life-saving research.”
Gottlieb resigns at FDA, recommends Sharpless as successor
Scott Gottlieb has submitted a letter of resignation from his job as FDA commissioner, reportedly recommending that NCI Director Ned Sharpless be appointed as his successor at the agency.
In Brief
- Raymond DuBois receives AACR Margaret Foti Award
- Charles Sawyers to present AACR Princess Takamatsu memorial lecture
- Alberto Mantovani receives Pezcoller Foundation-AACR Award
- Jeffrey Bluestone to receive AACR-Irving Weinstein Foundation lectureship award
- Manuel Hidalgo named chief of hematology and medical oncology at Weill Cornell
- Greg Delgoffe to receive Sy Holzer Endowed Immunotherapy Research Fund
Funding Opportunities
FDA Oncology Center of Excellence publishes research contract opportunities
The FDA Oncology Center of Excellence seeks white papers to award contracts for oncology regulatory science research through a Broad Agency Announcement, FDABAA-19-00123.
Clinical Roundup
- Genentech submits sNDA for Venclexta plus Gazyva for previously untreated CLL
- Study: AI may perform as well as radiologists
Drugs & Targets
- Paige.AI receives FDA Breakthrough Device designation
- Lynparza receives positive EU CHMP opinion in breast cancer
- Breast Cancer Index receives expanded Medicare coverage
NCI Trials
NCI Trials for March
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

Page 4 of 107«1 2 345 6 7 8 9 10...20 30 40 50 60 70 80 90 100...»Last »